Renoprotective Effects of SGLT2 Inhibitors

Heart Fail Clin. 2022 Oct;18(4):539-549. doi: 10.1016/j.hfc.2022.03.005.

Abstract

SGLT2 inhibitors can protect the kidneys of patients with and without type 2 diabetes from failing. This includes blood glucose dependent and independent mechanisms. SGLT2 inhibitors lower glomerular pressure and filtration, thereby reducing the physical stress on the filtration barrier and the oxygen demand for tubular reabsorption. This improves cortical oxygenation, which, together with lesser tubular glucotoxicity and improved mitochondrial function and autophagy, can reduce proinflammatory and profibrotic signaling and preserve tubular function and GFR in long term. By shifting transport downstream, SGLT2 inhibitors may mimic systemic hypoxia and stimulate erythropoiesis, which improves oxygen delivery to the kidney and other organs.

Keywords: Chronic kidney disease; Diabetic nephropathy; Hyperfiltration; Proximal tubule; SGLT2 inhibitor; Tubuloglomerular feedback.

Publication types

  • Review

MeSH terms

  • Blood Glucose
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetic Nephropathies* / prevention & control
  • Glomerular Filtration Rate
  • Humans
  • Oxygen / pharmacology
  • Sodium-Glucose Transporter 2 / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Blood Glucose
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Oxygen